Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of quercetin and kaempferol

A technology of quercetin and kaempferol, applied in the field of medicine, can solve problems such as growth retardation and chronic steroid weight gain, and achieve the effects of enhancing contractile function, preventing the accumulation of H2O2 and ROS, and reducing DNA damage

Pending Publication Date: 2021-06-25
SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently, DMD is treated primarily with steroids (to slow muscle deterioration) and beta-blockers (to relieve heart failure), but chronic steroid use has risks including weight gain, growth retardation, and fracture risk significant side effects of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of quercetin and kaempferol
  • New application of quercetin and kaempferol
  • New application of quercetin and kaempferol

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1 Culture of IPS cells (iPSCs) and differentiation of cardiomyocytes

[0065] 1. Induced pluripotent stem cells (hiPSCs) from healthy people and induced pluripotent stem cells (DMD hiPSCs) from patients with Duchenne muscular dystrophy were respectively used in NutristemhPSC XF medium on culture plates coated with Matrigel (purchased from Corning Company) (purchased from Biological Industries, Inc.) and cultured, and differentiated in the direction of the myocardium when growing to a density of 70-90%.

[0066] 2. Preparation of medium: RPMI1640 medium + B27 minus insulin (prepared according to the ratio of 10ml B27 + 500ml RPMI1640). Part of the RPMI1640 medium + B27minus insulin was added to CHIR (purchased from Selleck Chemicals) to a final concentration of 6 μM.

[0067] 3. Discard the medium in the IPS cell culture dish, add the CHIR-containing RPMI1640+B27minus insulin medium prepared in step 2), and culture continuously for 48 hours.

[0068] 4. Then re...

Embodiment 2

[0072] The measurement of reactive oxygen species (ROS) level in embodiment 2 cardiomyocytes

[0073] 1. Invitrogen CellRox dye was used to measure the level of reactive oxygen species in cardiomyocytes of healthy people and DMD cardiomyocytes.

[0074] 2. The two kinds of cardiomyocytes were incubated with CellRox and nuclear dye Hoechst 33342 at 37°C for 30 min, washed once with PBS, and then the fluorescence signal intensity was measured by Operetta CLS high-content imaging system with 20× numerical aperture. The result is as figure 1 shown.

Embodiment 3

[0075] Example 3 Determination of Myocyte Mitochondrial Superoxide Level

[0076] 1. Mitosox dye from Invitrogen Company was used for the measurement of mitochondrial superoxide levels in two kinds of cardiomyocytes.

[0077] 2. The two kinds of cardiomyocytes were incubated with Mitosox and nuclear dye Hoechst 33342 at 37°C for 30 min, washed once with PBS, and then the fluorescence signal intensity was measured by Operetta CLS high-content imaging system with 20× numerical aperture. The result is as figure 2 shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to application of quercetin and kaempferol in preparation of products for preventing or treating hereditary cardiomyopathy. The hereditary cardiomyopathy comprises dilated cardiomyopathy, hypertrophic cardiomyopathy and restricted cardiomyopathy. According to the product for preventing or treating cardiomyopathy, accumulation of active oxygen in myocardial cells and superoxide in mitochondria is reduced, intracellular DNA damage caused by ROS accumulation is relieved, the contractility of the myocardial cells is increased, and cardiomyopathy is prevented or treated. The new application of the quercetin and the kaempferol provides a new choice for development of drugs for preventing or treating the hereditary cardiomyopathy, expands the application range of the quercetin and the kaempferol, provides a new direction for clinical treatment of the hereditary dilated cardiomyopathy, and also brings a new vitality for clinical application of Chinese herbal medicine substances.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the new application of quercetin and kaempferol. Background technique [0002] Hereditary dilated cardiomyopathy (dilated cardiomyopathy, DCM) is characterized by ventricular dilatation and decreased systolic function. Among them, DCM patients bear the risk of reduced quality of life, high economic burden and sudden cardiac death along with heart failure. At present, patients with idiopathic / familial heart failure in my country are using drugs such as β-blockers (β-blockers) and angiotensin-converting enzyme inhibitors (Angiotensin-Converting Enzyme Inhibitors, ACEI) to delay the progress of heart failure. , however, except for a small number of heart transplant patients, the condition of most patients continued to deteriorate. [0003] Duchenne muscular dystrophy (DMD), caused by loss of expression of dystrophin, is an X-linked genetic disease that affects approximately 1:3500...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/7048A61P9/00A61P9/06A61P9/04A23L33/105
CPCA61K31/352A61K31/7048A61P9/00A61P9/06A61P9/04A23L33/105A23V2002/00
Inventor 张家毓李宾
Owner SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com